BBIO - BridgeBio Pharma, Inc.

QQQ $ 632.24 $ 0.00 (0 %)

DIA $ 474.50 $ 0.00 (0 %)

SPY $ 684.49 $ 0.00 (0 %)

TLT $ 90.45 $ 0.00 (0 %)

GLD $ 365.83 $ 0.00 (0 %)

Previous Close

$ 66.62

Open

$ 69.24

Bid

$ 64.54 x 100

Ask

$ 66.62 x 9

Day's Range

-- - --

52 Week Range

$ 21.72 - $ 69.48

Volume

7,434,955

Average Volume

Market Cap

12.84B

Beta (5Y Monthly)

$ 1.21

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-29-2025	09-30-2025	10-Q
2	08-05-2025	06-30-2025	10-Q
3	04-29-2025	03-31-2025	10-Q
4	02-20-2025	12-31-2024	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-01-2024	06-30-2024	10-Q
7	05-02-2024	03-31-2024	10-Q
8	02-22-2024	12-31-2023	10-K
9	11-02-2023	09-30-2023	10-Q
10	08-03-2023	06-30-2023	10-Q
11	05-04-2023	03-31-2023	10-Q
12	02-23-2023	12-31-2022	10-K
13	11-03-2022	09-30-2022	10-Q
14	08-04-2022	06-30-2022	10-Q
15	05-05-2022	03-31-2022	10-Q
16	02-25-2022	12-31-2021	10-K
17	11-04-2021	09-30-2021	10-Q
18	08-05-2021	06-30-2021	10-Q
19	05-06-2021	03-31-2021	10-Q
20	02-25-2021	12-31-2020	10-K
21	11-05-2020	09-30-2020	10-Q
22	08-11-2020	06-30-2020	10-Q
23	05-14-2020	03-31-2020	10-Q
24	03-03-2020	12-31-2019	10-K
25	11-08-2019	09-30-2019	10-Q
26	08-14-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Truist Securities Reiterates Buy on Bridge...
10/30/2025 12:32:21

Truist Securities analyst Danielle Brill reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target fr...

BridgeBio Pharma Q3 EPS $(0.95) Misses $(0...
10/29/2025 20:02:13

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(...

bridgebios-investigation-drug-outperforms-standard-therapy-in-rare-calcium-disorder

BridgeBio's Investigation Drug Outperforms...
10/29/2025 18:22:58

BridgeBio's Encaleret met its Phase 3 endpoint in ADH1, with 76% achieving calcium targets, supporting plans for FDA and EM...

HC Wainwright & Co. Maintains Buy on Bridg...
10/29/2025 17:44:31

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price ...

Earnings Scheduled For October 29, 2025
10/29/2025 11:11:56

Bridgebio Pharma Announced Topline Results...
10/29/2025 11:11:30

The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints.The ...

12 Health Care Stocks Moving In Tuesday's ...
10/28/2025 21:13:44

BridgeBio Pharma To Release Topline Phase ...
10/28/2025 20:04:29

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company fo...

Earnings Outlook For BridgeBio Pharma
10/28/2025 16:01:47

HC Wainwright & Co. Maintains Buy on Bridg...
10/28/2025 11:50:17

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price ...

janus-henderson-avidity-biosciences-bridgebio-pharma-and-other-big-stocks-moving-higher-on-monday

Janus Henderson, Avidity Biosciences, Brid...
10/27/2025 14:21:30

BridgeBio Announces All Primary And Second...
10/27/2025 11:02:49

BridgeBio Pharma To Host Webinar On Limb-g...
10/24/2025 20:03:58

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company fo...

Raymond James Maintains Outperform on Brid...
10/21/2025 17:52:19

Raymond James analyst Martin Auster maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target f...

bridgebios-acoramidis-cuts-risk-within-weeks-in-rare-heart-condition

BridgeBio's Acoramidis Cuts Risk Within We...
09/29/2025 14:42:14

BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study.

Reported Sunday, BridgeBio Pharma Says Aco...
09/29/2025 06:36:55

By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placeboAcoramidis significantly reduc...

BridgeBio Pharma To Highlight One Late Bre...
09/22/2025 11:34:16

HC Wainwright & Co. Reiterates Buy on Brid...
09/15/2025 11:50:33

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $70 pr...

UBS Maintains Buy on BridgeBio Pharma, Rai...
09/12/2025 14:26:55

UBS analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $72 to $82.

'BridgeBio Says Pfizer, Alnylam Aren't Pla...
09/11/2025 18:47:11

https://www.bloomberg.com/news/articles/2025-09-11/bridgebio-says-pfizer-alnylam-aren-t-playing-fair-in-blockbuster-race?embedd...

The Smart Money Is Buying These 10 Stocks
05/20/2025 20:50:22